Clinical Trials Browser

Interventional × Carcinoma, Transitional Cell × Mitomycin × Clear all

Carcinoma, Transitional Cell

NCT06331299 2026-01-15

UTOPIA

Phase 3 Active not recruiting

99 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07189793 2025-09-24

OHAI-NMIBC-01

Phase 2 Not yet recruiting

106 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT03658304 2024-11-05

Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma

Phase 2 Completed

29 enrolled 11 charts

Genitourinary

Carcinoma, Transitional Cell

NCT05243550 2024-11-04

ENVISION

Phase 3 Active not recruiting

240 enrolled 20 charts 1 FDA

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05136898 2024-09-19

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)

Phase 3 Completed

8 enrolled 18 charts

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06462001 2024-06-17

BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer

Phase 3 Active not recruiting

500 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT04688931 2024-06-06

ATLAS

Phase 3 Terminated

282 enrolled 29 charts

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01438112 2021-04-14

BOND

Phase 2/3 Terminated

22 enrolled

Genitourinary

Adenoviridae Infections, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Virus Diseases

NCT02793128 2020-12-22

Olympus

Phase 3 Completed

71 enrolled 16 charts 2 FDA

Genitourinary

Carcinoma, Carcinoma, Transitional Cell

NCT04006691 2020-05-07

Retreatment

Phase 3 Withdrawn

Genitourinary

Carcinoma, Carcinoma, Transitional Cell

NCT02982395 2019-08-30

Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC

Phase 3 Terminated

36 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma, Transitional Cell

Clinical Trials

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

UTOPIA

OHAI-NMIBC-01

Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma

ENVISION

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)

BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer

ATLAS

BOND

Olympus

Retreatment

Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC